Attorney Docket No.:

DEX-0075

Inventors:

Macina and Sun

Serial No.:

09/618,596

Filing Date:

July 17, 2000

Page 3

## REMARKS

Claim 1 is pending in the instant application. Claim 1 has been rejected. Claim 1 has been amended. No new matter is added by this amendment. Reconsideration is respectfully requested in light of this amendment and the following remarks.

## I. Rejection of Claim 1 under 35 U.S.C. § 112, second paragraph

Claim 1 has been rejected under 35 U.S.C. § 112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. In particular, the Examiner suggests that claim 1 is vaque and indefinite in the recitation "determining levels of colon specific gene. The Examiner suggests that it is unclear how the gene is measured. Thus, in an earnest effort to advance the prosecution of this case, and in accordance with the Examiner's suggestion, Applicants have amended the claim to delete the phrase and make clear that levels of a polynucleotide comprising SEQ ID NO:1 or the polypeptide encoded thereby are determined.

Withdrawal of this rejection under 35 U.S.C. § 112, second paragraph is respectfully requested in light of the amendments to the claim.

Attorney Docket No.:

DEX-0075

Inventors:

Macina and Sun

Serial No.: Filing Date: 09/618,596 July 17, 2000

Page 4

## Provisional Obviousness-type Double Patenting Rejection II.

Claim 1 has been provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of copending U.S. Patent Application No. 09/700,769 (filed January 4, 2001). The Examiner suggests that while the instant application specifies that the CSG comprises a polynucleotide of SEQ ID NO:1 or the encoded polypeptide, the broad claim of application '769 encompasses any CSG.

It is respectfully pointed out, however, that an amendment was filed in copending U.S. Patent Application 09/700,769 on July 1, 2004 wherein claim 1 was canceled and new claim 7 drawn to measuring levels of a polynucleotide comprising SEQ ID NO:3 or native protein encoded by SEQ ID NO:3 was presented. Thus, claims of copending U.S. Patent Application 09/700,769 are no longer drawn broadly to encompass any CSG.

Withdrawal of this provisional obviousness-type double patenting rejection is therefore respectfully requested.

## III. Conclusion

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly,

Attorney Docket No.: DEX-0075

Inventors:

Macina and Sun

Serial No.:

09/618,596

Filing Date:

July 17, 2000

Page 5

favorable reconsideration and subsequent allowance of the pending claims is earnestly solicited.

Respectfully submitted,

Registration No. 38,350

Date: July 27, 2004

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053 (856) 810-1515